MT2015-20: Biochemical Correction of Severe EB by Allo HSCT and Serial Donor MSCs

PHASE2CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

November 15, 2022

Study Completion Date

July 26, 2023

Conditions
Epidermolysis Bullosa
Interventions
DRUG

Thymoglobulin

0.5 mg/kg IV over 6 hours on day -9 and 2 mg/kg IV over 4 hours on day -8 and day -7 with premeds and solumedrol through day -2

DRUG

Cyclophosphamide

14.5 mg/kg IV over 1 hour day -6 and -5 50 mg/kg IV over 2 hours with mesna 40 mg/kg IV day +2 and +3

DRUG

Fludarabine

30 mg/m2 IV over 60 minutes days -6 through day -2

RADIATION

Total Body Irradiation

See arm description for dosing.

PROCEDURE

Bone marrow infusion

Bone marrow infusion on Day 0

DRUG

Tacrolimus

Day +5 through day +100 with goals of 5-10 ug/L (not used for HLA-identical related donors). When used in non-MSD recipients, tapered over 6-8 weeks starting at day +100.

DRUG

Mycophenolate Mofetil

15 mg/kg IV q8h (based upon actual body weight) with the maximum total daily dose not to exceed 3 grams. Day +5 through day 35

BIOLOGICAL

Donor mesenchymal stem cell infusions

Day 60, 100 and 180 (collected during donor BM harvest for graft)

DRUG

Busulfan

busulfan IV over 3 hours on days -3 and -2 for HLA-mismatched BM recipients only (Arms F and G)

Trial Locations (1)

55455

University of Minnesota Masonic Cancer Center and Medical Center, Minneapolis

All Listed Sponsors
lead

Masonic Cancer Center, University of Minnesota

OTHER

NCT02582775 - MT2015-20: Biochemical Correction of Severe EB by Allo HSCT and Serial Donor MSCs | Biotech Hunter | Biotech Hunter